基底细胞癌（BCC）细胞在手术切除标本的一个或多个边缘处的组织病理学存在被认为是不完全肿瘤清除的提示。不完全切除的BCC的处理可能因不同的临床情况而有所不同，从再切除到其他治疗或观察等方式都有可能。本研究旨在报告三级转诊中心不完全切除BCC的实际处理方式，并比较按选择的处理方式所选的复发率。本研究是在希腊北部一个三级皮肤科中心进行的一项回顾性研究。在5年期间，我们扫描了我们的电子数据库以检索所有具有可用组织病理学检测报告且至少有一个受累边缘（侧面或深层）的BCC。按不完全切除后选择的治疗分为3组：第1组包括进行即时再切除的病人（n=26），第2组包括随访但不进行任何额外治疗的病人（n=40），第3组包括接受辅助/非手术治疗的病人（n=18）。最后，我们记录了被选中再次切除（组1）肿瘤的新组织病理学检测报告中是否存在残留肿瘤。主要观察指标是临床肿瘤复发的出现率。在我们的数据库中记录的1689例BCC中，有84例符合纳入标准并被纳入分析。在84名患者中，有26名选择再次切除（组1），40名选择随访（组2），18名接受了辅助/非手术治疗（组3）。被再次切除的组1中的26个肿瘤的组织病理学报告显示，在14个（53.8％）案例中存在残留肿瘤。总体而言，在平均随访时间为17个月后，84名患者中有14名（16.7％）出现临床复发。无任何治疗的40名患者中，出现复发的有10人（25％），而只有18名接受非手术治疗的患者中有2人（11.1％）复发。本研究表明BCC切除后出现阳性组织病理学受累边缘仅在部分患者中会导致临床复发。当不采取任何进一步治疗时，此比率较高，当局部区域再次切除或单独或联合使用Imiquimod治疗时，此比率较低。

The histopathologic presence of basal cell carcinoma (BCC) cells at one or more margins of the specimen after surgical excision is considered suggestive of incomplete tumor clearance. The management of incompletely excised BCC might vary in different clinical scenarios from re-excision to application of other treatmenents or even watchful waiting.Τo report the real-life management of incompletely excised BCC in a tertiary referral center and compare the recurrence rates according to the selected management modality.A retrospective study was conducted at a tertiary Dermatology Center in Northern Greece. Our electronic database was scanned over a 5-year period to retrieve all BCCs with available histopathologic assay reporting at least one involved margin (lateral or deep). The included patients were divided into 3 groups according to the selected management after incomplete excision: group 1 included those who underwent immediate re-excision (n=26), group 2 those who were followed-up without any additional therapy (n=40) and group 3 those who were treated with adjuvant/complementary non-surgical treatment (n=18). Finally, we recorded the presence or absence of residual tumor in the new histopathologic report of those tumors that were selected to be re-excised (group 1). The primary outcome was the appearance of clinical tumor recurrence.Of 1689 BCCs recorded in our database, 84 met the inclusion criteria and were included in the analysis. Re-excision had been selected in 26 of 84 patients (group 1), watchful waiting in 40 (group 2) and non-surgical treatments in 18 (group 3). The histopathologic reports of the 26 tumors of group 1 that were re-excised revealed residual tumor in 14 (53.8%) cases. Overall, a clinical recurrence occurred in 14 of 84 patients (16.7%) after a mean follow up of 17 months. The median time to recurrence was 14 months. Of 40 patients without any treatment, recurrence developed in 10 (25%), while only 2 of 18 patients treated with non-surgical treatments recurred (11.1%).Our study suggests that positive histopathologic margins after BCC excision result in a clinical recurrence only in a proportion of patients. This percentage is higher when no further treatment is applied and lower when the area is re-excised or treated with imiquimod alone or combined with cryotherapy.S. Karger AG, Basel.